Charles River Laboratories to Acquire Cognate BioServices to Create a Premier Scientific Partner for Cell and Gene Therapy Development
Go back to Charles River Laboratories to Acquire Cognate BioServices to Create a Premier Scientific Partner for Cell and Gene Therapy Development| CHARLES RIVER LABORATORIE (NYSE: CRL) | Delayed: 188.29 +0.23 (0.12%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $188.06 | 52 Week High | $89.18 | |||
| Open | $186.91 | 52 Week Low | $65.70 | |||
| Day High | $190.79 | P/E | 87.58 | |||
| Day Low | $185.16 | EPS | $2.15 | |||
| Volume | 228,770 | |||||
